Northwest Biotherapeutics has partnered with the UK National Health Service Blood and Transplant (NHSBT) to support production of its experimental cancer vaccine DCVax-L, targeting glioblastoma and other solid tumors. NHSBT's therapeutic apheresis and cell processing teams in Leeds and Oxford are involved in collecting immune cells and processing them for the personalized vaccine. The collaboration aims to expand production capabilities across England, improving accessibility to this advanced immunotherapy. This partnership leverages NHSBT's expertise and facilities to scale up DCVax-L manufacturing as the vaccine undergoes regulatory review in the UK.
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant collaboration is noted here with Pluang's health sector market data as of Oct 09, 2026 03:21 WIB. Of 128 priced health-sector US stocks tradable on Pluang, 51 rose and 76 fell today. Notable movers include AbCellera Biologics Inc (ABCL) at USD 12.06 with a 1-day change of -6.00%, CVS Health Corp (CVS) at USD 83.45 down 5.12%, and Immunovant Inc. (IMVT) at USD 30.43 down 5.02%.
SpaceX is expanding its AI infrastructure to support its rocket launches, Starlink satellite network, and future AI growth plans. Analysts show mixed but generally positive sentiment, with Morgan Stanley maintaining a Buy rating and a $300 price targ...
Byrna Technologies reported a fiscal Q3 loss of $0.13 per share, better than the expected $0.16 loss, but revenue fell 46% year-over-year to $15.3 million, missing estimates. The company shifted from net income to a $2.9 million net loss due to weake...
On October 8, 2026, several stocks including AngioDynamics, Apimeds Pharmaceuticals US, and Arqit Quantum experienced steep declines of over 18%, despite some positive financial reports. Leveraged ETFs CRWG and IRE also dropped 15.5%, highlighting th...
On October 8, 2026, Pacira BioSciences surged 44.4% following Viatris' agreement to acquire the company for $36.50 per share, valuing the deal at approximately $1.65 billion. Other notable gainers included Profound Medical, which rose 21.7% after for...
Njord Luxco, a major shareholder jointly controlled by entities under Brookfield Corporation, has sold all its shares and voting rights in TORM plc as of October 6, 2026. This marks a significant change in TORM's shareholder structure, potentially im...
